Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors during the central nervous system, conolidine modulates alternate molecular targets. A Science Advancements study uncovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availab... https://danielf936zgn0.onzeblog.com/profile